147 related articles for article (PubMed ID: 29672900)
1. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall.
Farah M; Nagarajan P; Torres-Cabala CA; Curry JL; Amaria RN; Wargo J; Tawbi H; Ivan D; Prieto VG; Tetzlaff MT; Aung PP
J Cutan Pathol; 2018 Jul; 45(7):545-549. PubMed ID: 29672900
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall.
Valero-Torres A; Prieto VG; Nagarajan P; Torres-Cabala CA; Tetzlaff MT; Curry JL; Ivan D; Aung PP
Am J Dermatopathol; 2017 Jun; 39(6):468-470. PubMed ID: 28525424
[TBL] [Abstract][Full Text] [Related]
3. Pigmented atypical fibroxanthoma.
Diaz-Cascajo C; Borghi S; Bonczkowitz M
Histopathology; 1998 Dec; 33(6):537-41. PubMed ID: 9870148
[TBL] [Abstract][Full Text] [Related]
4. Malignant melanoma with osteoclast-like giant cells: an unusual host response: immunohistochemical and ultrastructural study of three cases and literature review.
Al-Brahim N; Salama S
Am J Dermatopathol; 2005 Apr; 27(2):126-9. PubMed ID: 15798437
[TBL] [Abstract][Full Text] [Related]
5. Atypical fibroxanthoma-like melanoma with Touton-like giant cells.
Lee JS; Kossard S
Am J Dermatopathol; 2007 Oct; 29(5):480-1. PubMed ID: 17890920
[No Abstract] [Full Text] [Related]
6. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
7. Langerhans cell histiocytosis mimicking malignant melanoma: a diagnostic pitfall.
Billings TL; Barr R; Dyson S
Am J Dermatopathol; 2008 Oct; 30(5):497-9. PubMed ID: 18806499
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
9. Pigmented atypical fibroxanthoma: a tumor that may be easily mistaken for malignant melanoma.
Diaz-Cascajo C; Weyers W; Borghi S
Am J Dermatopathol; 2003 Feb; 25(1):1-5. PubMed ID: 12544091
[TBL] [Abstract][Full Text] [Related]
10. Melanoma mimicking atypical fibroxanthoma: Report of an unusual case.
Wang Y; Guo Y
J Cutan Pathol; 2021 Dec; 48(12):1493-1496. PubMed ID: 34258786
[TBL] [Abstract][Full Text] [Related]
11. Melanoma masquerading as xanthogranuloma: a diagnostic pitfall.
Idriss MH; De Jesús G; McClain SA; Gottlieb GJ
Am J Dermatopathol; 2013 May; 35(3):e41-4. PubMed ID: 23190508
[TBL] [Abstract][Full Text] [Related]
12. Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Simetić L; Blažičević K; Međugorac K; Golčić M; Herceg D
Anticancer Res; 2020 Apr; 40(4):2157-2163. PubMed ID: 32234909
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potential biomarker for immunotherapy of melanoma: PLAC1 as an emerging target.
Mahmoudi AR; Ghods R; Rakhshan A; Madjd Z; Bolouri MR; Mahmoudian J; Rahdan S; Shokri MR; Dorafshan S; Shekarabi M; Zarnani AH
Immunopharmacol Immunotoxicol; 2020 Dec; 42(6):604-613. PubMed ID: 33106058
[TBL] [Abstract][Full Text] [Related]
14. Atypical fibroxanthoma with pseudoangiomatous features: a histological and immunohistochemical mimic of cutaneous angiosarcoma.
Thum C; Husain EA; Mulholland K; Hornick JL; Brenn T
Ann Diagn Pathol; 2013 Dec; 17(6):502-7. PubMed ID: 24080496
[TBL] [Abstract][Full Text] [Related]
15. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
16. Histiocytoid Melanoma.
Harvey NT; Grewal J; Ardakani NM; Robinson C; Leecy TN; Forrest C; Texler M; Kattampallil J; Lam M; Wallace C; Lum D; Wood BA
Am J Dermatopathol; 2020 Jun; 42(6):423-431. PubMed ID: 31725485
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
18. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma.
Miller K; Goodlad JR; Brenn T
Am J Surg Pathol; 2012 Sep; 36(9):1317-26. PubMed ID: 22510760
[TBL] [Abstract][Full Text] [Related]
19. Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.
Miyazawa H; Yanagi T; Yamaguchi Y; Imafuku K; Kitamura S; Hata H; Uehara J; Ichikawa N; Ohno Y; Yoshida T; Homma S; Kawamura H; Taketomi A; Shimizu H
J Dermatol; 2017 Aug; 44(8):959-962. PubMed ID: 28295515
[TBL] [Abstract][Full Text] [Related]
20. Malignant melanoma showing a rapid response to nivolumab.
Tsutsumi M; Asai J; Wada M; Takenaka H; Katoh N
Australas J Dermatol; 2016 Feb; 57(1):61-3. PubMed ID: 25854419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
